MK-4621 (RGT100)

MK-4621 (RGT100) · Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MK-4621 (RGT100), covering 2019-07-16 to 2019-07-16. Get the full timeline:

Most recent: Clinical Trial Update: Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001/RGT100-001) [Phase 1, Phase 2]

See pricing